{"id":707,"date":"2010-11-17T16:45:48","date_gmt":"2010-11-17T15:45:48","guid":{"rendered":"http:\/\/www.pjh.fr\/wordpress\/?p=707"},"modified":"2011-10-19T01:38:42","modified_gmt":"2011-10-18T23:38:42","slug":"larsenic-ameliore-la-survie-dans-la-la-promyelocytaire","status":"publish","type":"post","link":"http:\/\/www.pjh.fr\/wordpress\/?p=707","title":{"rendered":"L&rsquo;arsenic en 1\u00e8re ligne dans la leuc\u00e9mie aigu\u00eb promy\u00e9locytaire ?"},"content":{"rendered":"<p><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20705755\" target=\"_blank\">Blood, 11 November 2010 &#8211; Volume 116, N\u00b019<\/a><\/p>\n<p>La LAM3 ou Leuc\u00e9mie aigu\u00eb promy\u00e9locytaire (APL en english) repr\u00e9sente 10-15% des LAM et est caract\u00e9ris\u00e9e par une pr\u00e9sentation clinique, une cytog\u00e9n\u00e9tique, un traitement et une \u00e9volution sp\u00e9cifique. Le <strong>traitement standard de premi\u00e8re ligne<\/strong> associe actuellement une chimioth\u00e9rapie \u00e0 base d&rsquo;anthracycline et l&rsquo;ATRA en induction suivi d&rsquo;une consolidation par chimioth\u00e9rapie puis un entretien comprenant de l&rsquo;ATRA. Cette approche permet un taux de RC d&rsquo;environ 90%. Le <strong>facteur pronostic le plus important au diagnostic est le taux de leucocytes<\/strong>. L&rsquo;<strong>arsenic trioxyde<\/strong> (As2O3) a \u00e9t\u00e9 approuv\u00e9 pour le traitement des patients en rechute permettant d&rsquo;obtenir pour la majorit\u00e9 des patients une RC. Cette \u00e9tude avait pour but de tester l&rsquo;ajout pr\u00e9coce de l&rsquo;arsenic en premi\u00e8re ligne chez des patients en RC.<\/p>\n<p>Ci-dessous, le \u00ab\u00a0design\u00a0\u00bb (en bon fran\u00e7ais) de l&rsquo;\u00e9tude :<\/p>\n<p style=\"text-align: left;\"><a href=\"http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/zh89991060550001.jpeg\" rel=\"lightbox[707]\"><\/a><a href=\"http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/zh89991060550001-1.jpg\" rel=\"lightbox[707]\"><img loading=\"lazy\" class=\"aligncenter size-full wp-image-728\" title=\"zh89991060550001-1\" src=\"http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/zh89991060550001-1.jpg\" alt=\"\" width=\"450\" height=\"480\" srcset=\"http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/zh89991060550001-1.jpg 450w, http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/zh89991060550001-1-281x300.jpg 281w\" sizes=\"(max-width: 450px) 100vw, 450px\" \/><\/a><br \/>\n518 patients ont \u00e9t\u00e9 enr\u00f4l\u00e9s dans l&rsquo;\u00e9tude (15-79 ans).<\/p>\n<p style=\"text-align: left;\"><strong>Pour l&rsquo;induction (commune aux deux bras) :<\/strong><\/p>\n<ul>\n<li>r\u00e9ponse : 90%<\/li>\n<li>d\u00e9c\u00e8s : 8%<\/li>\n<li>ATRA syndrome : 117 (37%)<\/li>\n<\/ul>\n<p style=\"text-align: left;\">\ufeff<strong>Consolidation<\/strong><\/p>\n<ul>\n<li>pas de d\u00e9c\u00e8s li\u00e9 au traitement<\/li>\n<li>pas de toxicit\u00e9 importante au niveau cardiaque (allongement du QTc) chez les patients trait\u00e9s par As2O3, pas plus de toxicit\u00e9 h\u00e9matologique non plus<\/li>\n<\/ul>\n<p><strong>L&rsquo;EFS et DFS sont am\u00e9lior\u00e9es significativement par l&rsquo;adjonction d&rsquo;As2O3 <\/strong>:<br \/>\n&#8211; EFS 3 ans : As2O3 80% vs 63% (p&lt;0.0001)<br \/>\n&#8211; DFS 3 ans : 90% vs 70% (p&lt;0.0001)<br \/>\n<strong>Alors que les survies sont comparables <\/strong>(86% vs 81% \u00e0 3 ans p=0.07)<\/p>\n<div class=\"gallery\"><dl class='gallery-item'>\n\t\t\t<dt class='gallery-icon landscape'>\n\t\t\t\t<a href='http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/OS.jpg' rel=\"lightbox[707]\"><img width=\"150\" height=\"150\" src=\"http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/OS-150x150.jpg\" class=\"attachment-thumbnail size-thumbnail\" alt=\"\" loading=\"lazy\" srcset=\"http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/OS-150x150.jpg 150w, http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/OS-36x36.jpg 36w, http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/OS-110x110.jpg 110w\" sizes=\"(max-width: 150px) 100vw, 150px\" \/><\/a>\n\t\t\t<\/dt><\/dl><dl class='gallery-item'>\n\t\t\t<dt class='gallery-icon landscape'>\n\t\t\t\t<a href='http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/DFS.jpg' rel=\"lightbox[707]\"><img width=\"150\" height=\"150\" src=\"http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/DFS-150x150.jpg\" class=\"attachment-thumbnail size-thumbnail\" alt=\"\" loading=\"lazy\" srcset=\"http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/DFS-150x150.jpg 150w, http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/DFS-36x36.jpg 36w, http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/DFS-110x110.jpg 110w\" sizes=\"(max-width: 150px) 100vw, 150px\" \/><\/a>\n\t\t\t<\/dt><\/dl><dl class='gallery-item'>\n\t\t\t<dt class='gallery-icon landscape'>\n\t\t\t\t<a href='http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/EFS.jpg' rel=\"lightbox[707]\"><img width=\"150\" height=\"150\" src=\"http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/EFS-150x150.jpg\" class=\"attachment-thumbnail size-thumbnail\" alt=\"\" loading=\"lazy\" srcset=\"http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/EFS-150x150.jpg 150w, http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/EFS-36x36.jpg 36w, http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/EFS-110x110.jpg 110w\" sizes=\"(max-width: 150px) 100vw, 150px\" \/><\/a>\n\t\t\t<\/dt><\/dl><br style=\"clear: both\" \/><dl class='gallery-item'>\n\t\t\t<dt class='gallery-icon landscape'>\n\t\t\t\t<a href='http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/25.Diapositive9.jpg' rel=\"lightbox[707]\"><img width=\"150\" height=\"150\" src=\"http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/25.Diapositive9-150x150.jpg\" class=\"attachment-thumbnail size-thumbnail\" alt=\"\" loading=\"lazy\" srcset=\"http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/25.Diapositive9-150x150.jpg 150w, http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/25.Diapositive9-36x36.jpg 36w, http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/25.Diapositive9-110x110.jpg 110w\" sizes=\"(max-width: 150px) 100vw, 150px\" \/><\/a>\n\t\t\t<\/dt><\/dl><dl class='gallery-item'>\n\t\t\t<dt class='gallery-icon portrait'>\n\t\t\t\t<a href='http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/zh89991060550001-1.jpg' rel=\"lightbox[707]\"><img width=\"150\" height=\"150\" src=\"http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/zh89991060550001-1-150x150.jpg\" class=\"attachment-thumbnail size-thumbnail\" alt=\"\" loading=\"lazy\" srcset=\"http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/zh89991060550001-1-150x150.jpg 150w, http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/zh89991060550001-1-36x36.jpg 36w, http:\/\/www.pjh.fr\/wordpress\/wp-content\/uploads\/2010\/11\/zh89991060550001-1-110x110.jpg 110w\" sizes=\"(max-width: 150px) 100vw, 150px\" \/><\/a>\n\t\t\t<\/dt><\/dl>\n\t\t\t<br style='clear: both' \/>\n\t\t<\/div>\n\n<p>Les auteurs ont \u00e9galement analys\u00e9s l&rsquo;\u00e9volution selon les groupes de risque (Faible risque : GB&lt; ou = 10 000 et Pl &gt; 40000, Interm\u00e9diaire : GB &lt; ou = 10000 et Pl &lt; ou = 40 000 et Risque \u00e9lev\u00e9 : GB &gt; 10 000). Les deux premiers groupes (risque faible et interm\u00e9diaire) ont en g\u00e9n\u00e9ral le m\u00eame pronostic, meilleur que le groupe des hyperleucocytaires.<\/p>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"2\" align=\"center\">\n<tbody>\n<tr>\n<td>Risque<\/td>\n<td>Faible<\/td>\n<td>Interm\u00e9diaire<\/td>\n<td>Elev\u00e9<\/td>\n<\/tr>\n<tr>\n<td>RC<\/td>\n<td>94%<\/td>\n<td>93%<\/td>\n<td>71%<\/td>\n<\/tr>\n<tr>\n<td>D\u00e9c\u00e8s pendant induction<\/td>\n<td>4%<\/td>\n<td>4%<\/td>\n<td>20%<\/td>\n<\/tr>\n<tr>\n<td>EFS, DFS, OS<\/td>\n<td colspan=\"2\">=<\/td>\n<td>&lt;<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Les patients de tout risque ont b\u00e9n\u00e9fici\u00e9 de l&rsquo;arsenic et on constate que la DFS pour les patients \u00e0 haut risque trait\u00e9s par arsenic est la m\u00eame que pour les deux autres groupes&#8230;<\/p>\n<p>Enfin, concernant le traitement de maintenance qui \u00e9tait \u00e9galement randomis\u00e9 (ATRA seul vs ATRA + purinethol, methotrexate), trop peu d&rsquo;\u00e9v\u00e9nements pour pouvoir d\u00e9tecter une diff\u00e9rence entre les deux bras actuellement mais une tendance en faveur du bras ATRA + chimio per os en DFS (p = 0.054)<\/p>\n<p>On attend donc les r\u00e9sultats de l&rsquo;essai fran\u00e7ais APL 2000 (conso chimio classique vs chimio atra vs chimio As2O3) pour savoir si l&rsquo;arsenic devient un des traitements standard de premi\u00e8re ligne de la LAM3&#8230;<br \/>\n<\/p>\n<div class=\"pdf24Plugin-cp\"> \t<form name=\"pdf24Form0\" method=\"post\" action=\"https:\/\/doc2pdf.pdf24.org\/wordpress.php\" target=\"pdf24PopWin\" onsubmit=\"var pdf24Win = window.open('about:blank', 'pdf24PopWin', 'resizable=yes,scrollbars=yes,width=600,height=250,left='+(screen.width\/2-300)+',top='+(screen.height\/3-125)+''); pdf24Win.focus(); if(typeof pdf24OnCreatePDF === 'function'){void(pdf24OnCreatePDF(this,pdf24Win));}\"> \t\t<input type=\"hidden\" name=\"blogCharset\" value=\"Cw1x07UAAA==\" \/><input type=\"hidden\" name=\"blogPosts\" value=\"MwQA\" \/><input type=\"hidden\" name=\"blogUrl\" value=\"yygpKbDS1y8vL9cryMrQSyvSL88vSikoSi0uBgA=\" \/><input type=\"hidden\" name=\"blogName\" value=\"C0gtKs7PS8xR8MovLQLR+WkKjgoeiam5iSX5OfnpmcUlAA==\" \/><input type=\"hidden\" name=\"blogValueEncoding\" value=\"gzdeflate base64\" \/><input type=\"hidden\" name=\"postId_0\" value=\"MzcwBwA=\" \/><input type=\"hidden\" name=\"postTitle_0\" value=\"81ErKi4szbdOLCpOzctMVkjNUzA8vKIoVSEnMz0vVSElMa9YISdRISe1NPnwytzMVIXEzPTSw6sVCorycysPr8zJT64sScwEqrcHAA==\" \/><input type=\"hidden\" name=\"postLink_0\" value=\"yygpKbDS1y8vL9cryMrQSyvSL88vSikoSi0u1rcvsDU3MAcA\" \/><input type=\"hidden\" name=\"postAuthor_0\" value=\"cylSCMhMzgcA\" \/><input type=\"hidden\" name=\"postDateTime_0\" value=\"MzIwNNA1NNQ1NFcwNLMyNLQysQAA\" \/><input type=\"hidden\" name=\"postContent_0\" value=\"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\" \/> \t\t<a href=\"https:\/\/www.pdf24.org\" target=\"_blank\" title=\"www.pdf24.org\" rel=\"nofollow\"><img src=\"http:\/\/www.pjh.fr\/wordpress\/wp-content\/plugins\/pdf24-post-to-pdf\/img\/pdf_32x32.png\" alt=\"\" border=\"0\" height=\"32\" \/><\/a> \t\t<span class=\"pdf24Plugin-cp-space\">&nbsp;&nbsp;<\/span> \t\t<span class=\"pdf24Plugin-cp-text\">Envoyer l'article en PDF<\/span> \t\t<span class=\"pdf24Plugin-cp-space\">&nbsp;&nbsp;<\/span> \t\t<input class=\"pdf24Plugin-cp-input\" style=\"margin: 0px;\" type=\"text\" name=\"sendEmailTo\" placeholder=\"Entrez l'adresse e-mail\" \/> \t\t<input class=\"pdf24Plugin-cp-submit\" style=\"margin: 0px;\" type=\"submit\" value=\"Envoyer\" \/> \t<\/form> <\/div>","protected":false},"excerpt":{"rendered":"<p>Blood, 11 November 2010 &#8211; Volume 116, N\u00b019 La LAM3 ou Leuc\u00e9mie aigu\u00eb promy\u00e9locytaire (APL en english) repr\u00e9sente 10-15% des LAM et est caract\u00e9ris\u00e9e par une pr\u00e9sentation clinique, une cytog\u00e9n\u00e9tique, un traitement et une \u00e9volution sp\u00e9cifique. Le traitement standard de premi\u00e8re ligne associe actuellement une chimioth\u00e9rapie \u00e0 base d&rsquo;anthracycline et l&rsquo;ATRA en induction suivi d&rsquo;une [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":723,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[87],"tags":[72,73],"_links":{"self":[{"href":"http:\/\/www.pjh.fr\/wordpress\/index.php?rest_route=\/wp\/v2\/posts\/707"}],"collection":[{"href":"http:\/\/www.pjh.fr\/wordpress\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.pjh.fr\/wordpress\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.pjh.fr\/wordpress\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.pjh.fr\/wordpress\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=707"}],"version-history":[{"count":15,"href":"http:\/\/www.pjh.fr\/wordpress\/index.php?rest_route=\/wp\/v2\/posts\/707\/revisions"}],"predecessor-version":[{"id":722,"href":"http:\/\/www.pjh.fr\/wordpress\/index.php?rest_route=\/wp\/v2\/posts\/707\/revisions\/722"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/www.pjh.fr\/wordpress\/index.php?rest_route=\/wp\/v2\/media\/723"}],"wp:attachment":[{"href":"http:\/\/www.pjh.fr\/wordpress\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=707"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.pjh.fr\/wordpress\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=707"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.pjh.fr\/wordpress\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}